...
机译:评估儿童口服剂型的吞咽性和适口性:M-CERSI儿科配方研讨会的报告
Eli Lilly and Company Lilly Corporate Center;
Department of Pharmacy Pharmacology and Postgraduate Medicine University of Hertfordshire;
Pfizer Inc. Worldwide Research and Development Pharmaceutical Sciences Drug Product Design;
Abbvie Inc;
Abbvie Inc;
Takeda Development Center Americas Inc;
Norwegian Medicines Agency;
Bristol-Myers Squibb;
Bristol-Myers Squibb;
Department of Pharmacy Institute of Biopharmaceutics and Pharmaceutical Technology Ernst Moritz;
Children; Pediatric formulations; Acceptability; Compliance; Adherence; Taste;
机译:评估儿童口服剂型的吞咽性和适口性:M-CERSI儿科配方研讨会的报告
机译:儿科患者口服剂型发展过程中可口性和可吞咽性评估的系统文献综述
机译:儿科口服剂型开发中可口性和可吞咽性评估当前实践的行业调查
机译:药物制剂中的添加剂制造 - 用于口服药物递送的可生物降解印刷剂型的发育
机译:具有药物独立制剂和可变控制释放的新型口服剂型。
机译:儿科配方工作组的报告:对儿童友好的口服剂量形式的状态的观点
机译:基于环糊精的基于细胞素的纳米龙作为儿科口腔液剂型的制定与评价,用于增强生物利用度和掩蔽苦味